Understanding metabolic and stress changes in mitochondrial disease. A case study in Leber’s Hereditary Optic Neuropathy by Monar Redondo, Ignacio et al.
 






Report Type D: Experimental + Investigation Project 
 
Centro de Investigaciones Biológicas ‘Margarita Salas’ - CSIC 




Understanding metabolic and stress 
changes in mitochondrial disease.  
A case study in Leber’s Hereditary Optic 
Neuropathy. 
Student: Ignacio Monar Redondo 
Advisor: Dr. Aurora Gómez-Durán 
Internal mentor: Dr. Teresa de Asua 
 






Introduction. Bibliographic revision. 3 
I. Mitochondria and OXPHOS 3 
II. Mitochondrial genome 4 
III. Mitochondrial diseases (MDs) 5 
A. Point mutations in the mtDNA 6 
B. Mutations affecting mitochondrial translation 7 
C. Major rearrangements of the mtDNA 8 
IV. Metabolic changes in MDs 8 
A. Conventional biomarkers 8 
B. Novel biomarkers 12 
V. Mitochondrial dysfunction and stress mechanisms 16 
A. mTORC1 17 
B. Integrated stress response (ISR) 17 
C. Role ATF4 in MDs 19 
Methods 20 
I. Bibliographic research 20 
II. Cell culturing 21 
III. Denaturing electrophoresis and Western blot analysis. 22 
IV. Real-time PCR quantification of transcripts. 23 
V. Statistical analysis and graphics 24 
Results 25 
Case-study: Unmasking the mechanisms of stress in cell lines with mutations causing            
LHON. 25 
A. eIF2A is activated in m.3460G>A 25 
B. mTORC1 is activated in m.11778G>A 27 
C. No differences are observed in PERK levels 28 
D. mtUPR is not activated in LHON cell lines 29 
E. ATF4 is transcriptionally downregulated in m.3460G>A cell line 30 
F. ER stress is not activated in cell lines carrying LHON mutations 31 






Mitochondria are organelles which perform various roles in the cell (mainly the energy             
production) and house their own genetic material, the mitochondrial DNA. Mutations in this             
genome and/or genes of the nuclear DNA affecting mitochondrial function are the cause of a               
set of rare pathologies (1 patient:5000 individuals) known as mitochondrial diseases (MDs).            
MDs comprise a wide range of disorders with high phenotypic variability and unknown             
molecular mechanisms, which limits their diagnosis and treatment. Recently, multi-omic          
approaches have emerged as a possible tool to identify new biomarkers and pathways             
involved in these pathologies pointing to fundamental metabolic routes such as the            
mechanistic target of rapamycin complex 1, the Integrated Stress Response and the            
Activating Transcription Factor 4. Here, we present a comprehensive review of the latest             
insights in the field, compiling recent publications on metabolomics as well as transcriptomic             
data trying to dissect the puzzle underlying the complexity MDs. In addition, we perform a               
case study on cell lines carrying two primary mutations causing Leber’s Hereditary Optic             
Neuropathy to investigate how different elements of cellular stress are altered in this disease.              





Introduction. Bibliographic revision. 
I. Mitochondria and OXPHOS 
Mitochondria are very complex and dynamic organelles constantly fussing and budding​1           
which synthesize the most of the energy of the cell in the form of adenosine triphosphate                
(ATP). Mitochondria are not only the powerhouse of the cell but also integrate multiple              
metabolic pathways, such as fatty acid oxidation, urea cycle, gluconeogenesis and           
ketogenesis. Furthermore, they play an important role in other cellular processes like            
non-shivering thermogenesis, amino acid metabolism, lipid metabolism, biosynthesis of         
haem and iron-sulfur clusters, calcium homeostasis and apoptosis​2​. 
 
Cells are able to produce reducing equivalents nicotinamide adenine dinucleotide (NAD(P)H)           
and flavin adenine dinucleotide (FADH​2​) by various metabolic routes. These molecules are            
reoxidized in the mitochondria in order to be recovered and cease their electrons to the               
electron transport chain (ETC). This process, together with the synthesis of ATP, is known              
as oxidative phosphorylation (OXPHOS). OXPHOS’s reactions take place in the inner           
membrane, which is heavily folded in order to increase its surface and achieve a higher               
activity. OXPHOS is formed by five complexes (named I - V) and two mobile electrons               
carriers (CoQ/ubiquinone and cytochrome C). All the elements of the ETC are arranged (Fig.              
1) in increasing order of potential of reduction, so that the electrons flow spontaneously              
following the thermodynamic rules. This makes it possible to generate energy through some             
endergonic reactions, which is accumulated as a gradient of protons (H​+​). Then, the complex              
V - ATP synthase is able to leverage this energy transforming it into ATP molecules and                







Fig. 1: Schematic representation of oxidative phosphorylation. Taken from         
Gorman et al. (2016)2. Complex I (NADH:coenzyme Q oxidoreductase); coenzyme          
Q10 (CoQ); complex II (succinate-CoQ oxidoreductase); complex III        
(ubiquinol-cytochrome c oxidoreductase); complex IV (cytochrome c oxidase);        
complex V (ATP synthase). 
II. Mitochondrial genome 
Mitochondria house their own genome, codified in a circular molecule of double stranded             
DNA known as mitochondrial DNA (mtDNA). In mammals, it is maternally inherited and does              
not present recombination​4​. During fecundation, one of the few spermatozoa that reach the             
corona radiada destroys the zona pellucida by releasing digestive enzymes (contained in the             
acrosomes) and fuses with the oocyte membrane. Then, only the nuclear genetic material of              
the male is released onto the egg cytoplasm allowing pronucleus fusion and formation of the               
zygote. Thus, the only mtDNA inherited comes from the ovocyte​5​. 
 
The mtDNA molecule lacks histones and has a high density of coding sequences, similar to               
prokaryotic DNA​6​. It is 16,569 base pairs long and polyploid, being present in several copies               
in each single mitochondria, and thus per cell. This fact leads to the situation of               
heteroplasmy. Heteroplasmy happens when in a single mitochondrion/cell there are mtDNA           
molecules with alternative alleles in their sequence, providing a pool of mitochondrial            
genomes. Likewise, different cells might hold distinct heteroplasmy levels and variants,           
resulting in an unique distribution of alterations in each tissue, organ and individual which              




mtDNA encodes for 13 polypeptides of the oxidative phosphorylation system (OXPHOS),           
along with 22 transfer RNAs (tRNAs) and 2 ribosomal RNAs (rRNAs) necessary for the              
transcription and translation inside the mitochondria (Fig. 2). The remaining proteins involved            
in mitochondrial function (more than 1,500)​8 are encoded in the nuclear DNA (nDNA),             
synthesized in the cytosol and imported into the mitochondria​9​. These proteins include            
enzymes of mitochondrial metabolic routes, components of the ETC and assembly factors,            
chaperones, nucleases, carriers, ribosomal proteins, etc​8​. 
III. Mitochondrial diseases (MDs) 
Genetic variants in the genomes encoding for proteins involved in the mitochondrial function             
(mtDNA and/or nDNA) cause rare diseases known as mitochondrial diseases (MDs)​2​. These            
disorders are normally characterised by changes in mitochondrial function, affecting the           
bioenergetics and/or the metabolic network of the cell. MDs present a wide range of              
phenotypes with a multi-organic involvement​10 and a complex etiology, as one single            
mutation can result in several types of syndromes, or the opposite. For example, the              
m.3243A>G mutation in ​MT‑TL1 might cause chronic progressive external ophthalmoplegia          
(CPEO), lactic acidosis and stroke-like episodes syndrome (MELAS) and maternally inherited           
diabetes and deafness (MIDD)​5​. Nowadays, little is known about how these mutations affect             
different tissues and organs with such variable degree of severity​7​. Further knowledge on the              
molecular basis of these pathologies will benefit their diagnosis and discovery of effective             
therapies. 
 
Alterations in the mtDNA account for the majority of MDs in adults, while in children they are                 
less common as phenotypic manifestation requires a high level of heteroplasmy​2​. Point            
mutations in the mtDNA can either affect protein-encoding genes or disturb the protein             
synthesis inside the organelle, altering ​mt-tRNA and/or ​mt-rRNA genes​11​. We have selected            
some of the most studied MDs caused by point mutations and rearrangements in the mtDNA               
(representing most of the MDs patients) and classified them in whether they cause a point               
mutation in a gene encoding any of the OXPHOS complexes, a defect in the mitochondrial               





Fig. 2: The mitochondrial genome and map of mutations causing mitochondrial           
disorders in the mtDNA. Adapted from Biochemistry (C. Mathews)​3​. Colours pink,           
orange, blue and yellow show genes encoding for complex I, III, IV and V subunits,               
respectively. Green is used for genes encoding for rRNAs and black lines for tRNAs.              
Red and blue arrows highlight variants affecting mitochondrial translation and point           
mutations in OXPHOS complexes, respectively. 
 
A. Point mutations in the mtDNA 
Point mutations in the genes encoding for subunits of OXPHOS complexes cause a variety of               
disorders. One example for this type of disorders is the Leber’s Hereditary Optic Neuropathy              
(LHON), caused by missense mutations in the mtDNA that can act individually or in              
association with others. The three commonest mutations causing LHON are the           
non-synonym changes m.3460G>A/p.MT-ND1:A52T, m.11778G>A/ p.MT-ND4:R340H and      
m.14484T>C/ p.MT-ND6:M64V. These alterations affect polypeptides from complex I​12​. It is           
maternally inherited as it arises from a mtDNA alteration, affecting mostly young males​13​.             
LHON patients present acute or subacute central vision loss leading to scotoma or deafness.              
Alterations rising from these mutations affect selectively retinal ganglion cells (RGCs)           
functionality, but some cases can present cardiac and neurological abnormalities. Incomplete           




Another well studied MD caused by point mutations in a wide range of genes in either nDNA                 
or mtDNA is Leigh syndrome (LS)​15​. LS is a dramatic neurodegenerative disorder            
characterized by early deaths in childhood or young adulthood, normally not older than 3              
years. The most common genetic causes are defects in complex I, but reported cases              
involving other complexes, assembly factors, mtDNA maintenance and mitochondrial         
translation machinery have also been described​16​.  
 
A sub-type of LS is caused by mutations in the MT-ATP6 gene, which encodes for subunit 6                 
of complex V (CV) and is known as Maternally inherited LS (MILS). However, strinklingly the               
same mutations that cause MILS provoke Neuropathy, Ataxia and Retinitis Pigmentosa           
(NARP) depending on the heteroplasmy degree (mtDNA mutant content)​17​. When the levels            
of heteroplasmy are >80% causes LS (MILS) and is characterized by onset of symptoms              
typically between ages three and 12 months, with very bad pronostic as described above.              
But, when the heteroplasmic load is <80% causes NARP syndrome that can be relatively              
stable for many years and with a less acute phenotype. In both cases, the pathogenesis is                
thought to be caused by ATP synthesis impairment​18​. But other genetic factors such as the               
mtDNA background (collection of population variants on the mtDNA) might play a key role as               
it can derive in respiratory chain (RC) defects that contribute to phenotypic variability​19​. 
B. Mutations affecting mitochondrial translation 
MELAS syndrome can be caused by mutations in several mt-tRNA genes, but the most              
common is the mt.3243A>G conversion in the ​MT‑TL1 gene​20​. Rarely it can be caused by               
mutations in complexes I, III or IV. The clinical phenotype is variable and it includes               
neurological, muscular, cardiac and gastrointestinal manifestations and lactic acidemia​21​.         
Importantly, high heteroplasmy levels of m.3243A>G mutation affect neuronal network          
organization and activity​22​, which could stand for cognitive and psychiatric characteristics of            
MELAS. 
 
Highlighting the complexity of MDs, MIDD shares with MELAS the m.3243A>G mutation as             
the most common cause of the disease. Mutations in other mt-tRNA genes have also been               
related to MIDD​23​. It is characterized by hearing loss and diabetes, but patients can present               




Interestingly, patients harbouring the m.3243A>G mutation present a wide spectrum of           
phenotypic manifestations, ranging ​from MIDD to MELAS. It is commonly accepted that            
higher heteroplasmy levels lead to more severe affectations, but other factors such as             
mtDNA copy number​25​, environmental factors​26 or nuclear genetic factors​27 might also be            
determining in the final phenotype. Further investigation will hopefully allow us to identify             
these factors and unravel the pathophysiological mechanisms which participate in these and            
other mitochondrial disorders. 
C. Major rearrangements of the mtDNA 
Infantile Onset Spinocerebellar Ataxia (IOSCA) is caused by multiple deletions in the mtDNA             
mainly in skeletal muscle, derived from mutations in the nDNA encoded Twinkle helicase             
which disturbs mtDNA replication. Symptoms include difficulty to coordinate movements          
(ataxia), muscle weakness (hypotonia), involuntary writhing of the limbs (athetosis) and other            
neurodegenerative manifestations. It is autosomal recessively inherited and appears in          
children from 9-18 months​28​. 
 
Progressive external ophthalmoplegia (PEO) is a mitochondrial myopathy driven by          
mutations in the nDNA-encoded DNA polymerase gamma gene (​POLG​), which derives in            
multiple deletions in the mtDNA. It is characterized by weakness of the external eye              
muscles​29​. 
IV. Metabolic changes in MDs 
Mitochondria produce the majority of energy in the cell, but they are also an intersection point                
between multiple metabolic routes​30​. Thus, variants causing MDs also compromise several           
intra-mitochondrial OXPHOS catabolism that affect the function of other cytoplasmic signals           
and metabolites. Finding the ins and outs of these metabolic imbalance is crucial for              
diagnosis (disease biomarkers) and therapeutics of these disorders. 
A. Conventional biomarkers 
Several metabolic biomarkers have been traditionally used in diagnosis of MDs. Some of             




A classical biomarker in MDs is lactic acid or lactate (Table 1). Cells respond to the                
mitochondrial dysfunction performing homolactic fermentation. Under OXPHOS deficiency,        
the pyruvate originated from the glycolysis is stalled, accumulates and its transformed by the              
lactate dehydrogenase (LDH) into lactate (Fig. 3), that is then released to the body fluids,               
such as the blood and cerebrospinal fluid (CSF) causing lactic acidosis. The ratio of              
lactate:pyruvate is commonly employed as a biomarker in several MDs. However, their use is              
debatable, as many disorders such as ​Kearns-Sayre syndrome, LHON, and mitochondrial           
polymerase γ-associated patients do not show high lactate​31​. In addition, the measurement            
and analysis of lactate is complex and limited which makes its reliability uncertain​32,33​.             
Similarly, the pyruvate is also very unstable​34,35 and is often misestimated​31​. Besides, its             
increase can be a confounder of other metabolic diseases such as the pyruvate             
dehydrogenase (PDH) deficiency​36​. All together, these facts make them non-reliable,          
encouraging the discovery of new biomarkers. 
 
Several MDs show increased alanine levels​33 (Table 1). Alanine is produced from pyruvate             
and glutamate by the enzyme alanine transaminase (ALT) along with α-ketoglutarate (α-KG)            
(Fig. 3). Normally, an increase in the levels of alanine is a reflection of pyruvate               
accumulation​33​. Thus, it has been proposed as a viable biomarker when considered along             
with other metabolites​37​. Alanine measurement is also easier than lactate and pyruvate as it              
has higher stability during collection of the sample​33​. High levels of alanine have been              
observed in patients with IOSCA, MIRAS, PEO and MELAS/MIDD (see Table 1). Alterations             
in the levels of alanine are not exclusive to MDs but present in PDH and pyruvate                





Fig. 3: Scheme of the main sources of pyruvate production in the cell. TCA:              
tricarboxylic acid cycle; aKG: alpha ketoglutarate; Glu: glutamate; LDH: lactate          
dehydrogenase; ALT: alanine transaminase; PDH: pyruvate dehydrogenase; NADH:        
nicotinamide adenine dinucleotide; FADH2: flavin adenine dinucleotide; ATP:        
adenosine triphosphate. 
 
The third classical biomarker in MDs is creatine (Cr). Creatine acts as storage or transport of                
high-energy phosphate groups ensuring ATP/adenosine diphosphate (ADP) buffering​39 that         
allows the transfer of one phosphate group from ATP to yield phosphocreatine (PCr) and              
ADP through the creatine kinase (CK) reaction (Fig. 4). Under OXPHOS deficiency, and thus              
ATP depletion, the Cr accumulates by shifting the CK reaction into Cr production (Fig. 4).               
High Cr plasma levels have been reported in LS​40​, IOSCA​37​, MELAS and MERRF​41 (see              
Table 1). However, Cr in blood can be also affected by factors such as diet, exercise, age                 





Fig. 4: The creatine kinase (CK) reaction and the non-enzymatic production of creatinine. 
 
Carnitine has also been suggested as a potential MD biomarker as it is related to fatty acid                 
oxidation. Low acylcarnitines C3 and C5 levels have been reported in LHON fibroblasts​42​,             
and altered levels of other acylcarnitines (Table 1) have been found in LS patients​40​.              
Alterations in blood and urine concentrations of other organic acids - highlighting TCA cycle              
intermediates - also occur in MDs​33,41,43,44​. However, these findings do not provide a clear              
metabolic pattern in MDs and further investigation is needed. 
 
Similar to the described biomarkers, other molecules have been reported in isolated            
disorders. Some examples are the nitric oxide (NO) and arginine deficiency which are             
strikingly related to the pathogenesis of MELAS patients​45​. High levels of thymidine and             
deoxyuridine are characteristic of mitochondrial neurogastrointestinal encephalopathy       





Table 1: Alterations in levels of conventional biomarkers in MDs. The           
disease/treatment that causes the alteration are indicated. 
B. Novel biomarkers 
As previously discussed, one of the main problems regarding MDs diagnosis is the lack of               
specificity and/or sensitivity of the current biomarkers​2,47​. Discovering new molecules might           
help to find a better comprehension of the MDs, and for these reasons metabolomics              
approaches have emerged as a potential tool to precisely diagnose and monitor certain these              
disorders​48​. To date, a handful of metabolomic studies have been performed in MDs patients              
and mitochondrial deficiency models, with some metabolites rising as potential biomarkers           




One of the most common metabolic shifts in severe OXPHOS deficiencies is the drop of               
NAD​+​/NADH ratio, which occurs as NAD​+ decreases and NADH accumulates​40,49,50 (see           
Table 2). NAD​+ decline is a direct consequence of OXPHOS impairment, as NADH             
reoxidation mainly depends on the NADH:ubiquinone oxidoreductase (or mitochondrial         
complex I) (Fig. 1). NAD​+​/NADH reductions have been described in NARP/MILS syndrome​50​,            
IOSCA​37​, and LS​40​. However, despite being a common feature of MDs, NAD​+​/NADH ratio is              
also present in other metabolic disorders such as type 2 diabetes​51​. Therefore, although             
NAD​+​/NADH reduction might be used as an indicator of prevalence of mitochondrial            
dysfunction, it does not serve as a unique biomarker for diagnosis. 
 
Higher levels of serine have also been reported in multiple MDs, such as IOSCA, PEO,               
mitochondrial myopathy, encephalomyopathy, MELAS or MIDD​37 as well as under mtDNA           
depletion​52 (see Table 2). Serine synthesis is derived from glycolysis (specifically from            
3-phosphoglycerate)​53 (Fig. 5). Serine biosynthesis genes are upregulated under         
mitochondrial dysfunction​52​, therefore explaining this increase. 
 
Fig. 5: Scheme of the serine biosynthesis pathway​, in orange. Scheme of the             
glycolysis, in blue. G3P: glyceraldehyde-3-phosphate; PHGDH:      
D-3-phosphoglycerate dehydrogenase; PSAT1: phosphoserine aminotransferase;     
PSPH: phosphoserine phosphatase. 
 
Lately, glutamine metabolism has also gained attention as a possible starring biomarker in             
MDs. Glutamine is converted into glutamate via mitochondrial glutaminase (GLS)​54​.          
13 
 
Glutamate is the most abundant excitatory neurotransmitter, feeds an anaplerotic route into            
TCA cycle (Fig. 6) and is involved in glutathione (GSH) metabolism. Furthermore, shifting of              
glutamate transamination reactions is consistent with a drop in the NAD​+​/NADH ratio,            
commonly present in MDs​35,36​. Moreover, the glutamine-glutamate-α-KG anaplerotic route         
has been shown to be increased in OXPHOS-defective cell lines​55 and alterations in             
glutamine levels have been consistently described in several disorders such as LHON​42,56​,            
NARP/MILS​55 and/or Leigh syndrome​57 (see Table 2), which strongly supports          
glutamine-related metabolites as potential biomarkers in MDs. 
 
 
Fig. 6: Scheme of glutamine metabolism. Glutamine is part of an anaplerotic pathway that              
enters the tricarboxylic acid (TCA) cycle and is metabolized following oxidative (clockwise) or             
reductive (counterclockwise) carboxylation. OAA: oxaloacetate; aKG: alpha ketoglutarate;        
Gln: glutamine; Arg: arginine; His: histidine; Pro: proline; Thr: threonine; Iso: isoleucine; Met:             
methionine; Val: valine; GTP/ATP: guanosine/adenosine triphosphate; AMP: adenosine        





Another notable change in metabolism in MDs is the reduction observed in aspartate, a              
central molecule that links several metabolic routes (Fig. 7). On one hand, aspartate             
depletion promotes rewiring of glutamine metabolism by decreasing feedback inhibition by           
oxaloacetic acid (OAA) and glutamine-derived aspartate is used as a compensatory force to             
restore the NAD​+​/NADH balance​50,55​. On the other hand, oxidative carboxylation of glutamine            
leads to aspartate conversion into alanine and lactate (Fig. 7) thus increasing their levels              
(see Introduction, Section IV.A)​55​. Altogether, these observations point out to aspartate as a             
central metabolite in MDs. In keeping with this, aspartate depletion has been shown in              
LHON​42,56​, NARP​50​, and LS​55 as well as in cell models treated with OXPHOS inhibitors, such               
as rotenone, pierdicin A​42​, phenformin (CI inhibitors)​58​, doxycycline (impairing mitochondrial          




Fig. 7: Scheme of aspartate metabolism. MDH1/2: malate dehydrogenase 1 (cytosolic)           
and 2 (mitochondrial); GOT1/2: glutamic oxaloacetic transaminase 1 (cytosolic) and 2           
(mitochondrial); ASNS: asparagine synthase; AGC1/2: aspartate glutamate carrier 1         
(cytosolic) and 2 (mitochondrial); OGC: 2-oxoglutarate carrier; MGC1: mitochondrial         
glutamate carrier 1; OAA: oxaloacetate; aKG: alpha ketoglutarate; Glu: glutamate; Gln:           
glutamine; ATP: adenosine triphosphate; AMP: adenosine monophosphate; NADPH:        




Collectively, these findings suggest that alanine, glutamine and aspartate metabolism play a            
key role in the adaptive changes that happen in cells with OXPHOS impairment and should               
be strongly considered as a metabolic signature in MDs. 
 
Table 2: Alterations on various metabolites in MDs​, proposed as potential novel            
biomarkers. The disease/treatment that causes the alteration is indicated. 
V. Mitochondrial dysfunction and stress mechanisms 
Each new discovery in the landscape of MDs shows the complexity of its pathophysiology.              
Several evidences pinpoint that partial or total ATP depletion may not be the sole cause for                
the wide range of phenotypes observed in MDs​11​. Therefore, great effort has been made in               
revealing their underlying mechanisms. Other mechanisms have been proposed, such as           
overproduction of reactive oxygen species (ROS)​2,7,11​, metabolic rewiring (see Introduction,          
Section IV) or mitochondrial biogenesis impairment​60​. Nonetheless, further research has          
enlightened new key pathways. Here, we have focussed on the latest findings in MDs and               




The role of the mechanistic (mammalian) target of rapamycin complex I (mTORC1) is very              
interesting in this context. mTORC1 is a nutrient sensor that controls several processes such              
as protein synthesis, cell growth, ​de novo ​pyrimidine​61,62​, purine​63 and lipid synthesis, pentose             
phosphate pathway, and autophagy​64,65​. 
 
Recent data on a mouse model of mitochondrial depletion​66​, as well as human muscle              
samples​67​, have shown that mTORC1 is activated in mitochondrial stress. By using the             
mTORC1 inhibitor rapamycin, Prof. Suomalainen’s lab observed that the activation of           
mTORC1 has a myriad of functions driven by the induction of the activating transcription              
factor 4 (ATF4)​66​. Hyper-activation of the axis mTORC1-ATF4​63 acts as a compensatory            
mechanism to restore the dNTP pools as well as the metabolic rewiring of pentose              
phosphate pathways, which are both altered in this model of MDs. 
 
Interestingly, mTORC1 inhibition with rapamycin have also been shown to reduce           
heteroplasmy by removing defective mitochondria (mitophagy/autophagy) in cell modells of          
MELAS (m.3423G>A/MT-TL1) and LHON (m.11778G>A/p.MT-ND4:R340H)​68–70​, as well as        
increase the lifespan and alleviate symptoms in LS (​Ndufs4​-/-​)​57,71​, thymidine kinase 2 (TK2)             
deficiency (Tk2​KI/KI​)​72 and mitochondrial myopathy (Cox15​sm/sm​)​73 mouse models. However,         
rapamycin has not been effective on other types of MDs​74​, suggesting that mTORC1 might              
have different roles in the etiology of each disease. 
B. Integrated stress response (ISR) 
The term ISR was first coined by Ron​75 & Harding​76 in order to designate the convergence of                 
different stress responses into the phosphorylation of the alpha subunit of eukaryotic            
translation initiation factor 2 (eIF2A). Phosphorylation of eIF2A on serine 51 is performed by              
four eIF2A kinases (Fig. 8), and leads to the blockade of translation initiation of most               
messenger RNAs (mRNAs) by inhibiting the delivery of the Met-tRNAi to the ternary             
complex​77​. However, it favours the synthesis of a group of mRNAs that are normally poorly               
translated because they have two upstream open reading frames (uORFs). A case of these              
mRNAs with 2 uORFs is the known mitochondrial retrograde signaling agent ATF4​78 (see             




Recent research has pinpointed elements of the ISR as having a possible role in MDs.               
Activation of the PERK/eIF2A axis has been observed in LHON patient fibroblasts​42 and             
activation of eIF2A and downstream effectors of the ISR (ATF4, Activating Transcription            
Factor 5 (ATF5) and C/EBP homologous protein (CHOP)) has been seen in MELAS cell              
lines​70​. Additionally, activation of the eIF2A downstream target ATF4 occurs in MDs as             
extensively discussed below (see Introduction, Section V.C). Yet it is still not clear whether              
ISR activation is beneficial or detrimental to the patients with MDs​79​. 
 
 
Fig. 8: Scheme of the Integrated Stress Response (ISR). HRI: heme-regulated           
inhibitor kinase; PERK: protein kinase R-like endoplasmic reticulum kinase; GCN2:          
general control non-derepressible 2; PKR: protein kinase R; p - eIF2a:           
phosphorylated eukaryotic translation initiation factor 2 alpha; ATF4: activating         
transcription factor 4; PHGDH: phosphoglycerate dehydrogenase; PSAT1:       
phosphoserine aminotransferase 1; MTHFD2: methylenetetrahydrofolate     




C. Role ATF4 in MDs 
 
When subjected to stress conditions, mitochondria trigger various signaling pathways within           
the nucleus activating a transcriptomic response known as retrograde response​80​. Several           
recent evidence points out to the activation of ATF4 as one of the main regulators in this                 
response​81​. 
 
ATF4 belongs to the family of leucine zipper proteins, as it contains a bZIP domain​82​. It can                 
form homodimers or heterodimers with different proteins that modulate its concrete function.            
It mediates its transcriptional regulator activity through binding to C/EBP-ATF response           
element (CARE)​78,83​. ATF4 activation is present in amino acid deprivation​84​, endoplasmic           
reticulum (ER) stress​76,78​, cancer​85 as well as MDs (see below). Furthermore, ATF4 controls             
the expression of downstream effectors of the ISR and the mitochondrial Unfolded Protein             
Response (mtUPR)​86​, such as growth arrest and DNA damage-inducible protein (GADD34),           
CHOP​78 and ATF5​66,67​. Additionally, ATF4 controls other genes related to metabolic changes            
such as asparagine synthase (ASNS)​87​, serine biosynthesis genes, folate cycle genes​52​,           
fibroblast growth factor 21 (FGF21)​66,88,89 and Parkin​90 (Fig. 8) all known to be altered in               
different forms of MDs. How upregulation of these genes impacts MDs’ pathogenesis is             
unknown and has yet to be investigated. 
 
Several reports have shown ATF4 activation in MDs. It has been reported in cybrids              
harboring NARP mutations​87​, mouse and human (PEO patients) mitochondrial depletion​66          
and in MELAS cell lines harboring the m.3243G<A mutation.​70 Furthermore, several groups            
have observed ATF4 activation under pharmacologically induced mitochondrial dysfunction         
52,59,66,88​. Yet, the upstream regulators of ATF4 are still debatable and might change in              
different MDs. For instance, mTORC1 is activated in the Deletor mice​66 and the m.3243G>A              
cell line​70​. Moreover, mitochondrial stressors induce eIF2A phosphorylation​59,87​, but no          
increase is observed in NARP and MELAS cell lines​87​. Further investigation on the molecular              
mechanisms upstream of ATF4 is needed to unveil the role of these pathways in the               




I. Bibliographic research 
Literature research was made using the free-access search engine PubMed. At first, key             
bibliography about mitochondrial disease, metabolomics and mitochondrial stress was         
provided by Dr. Aurora Gómez-Durán, the leader of the lab. After consulting these             
references, I was capable of understanding the basics on the field and starting a              
bibliographic search by myself. Recent publications on the topic and more scientific articles             
were looked for using keywords and references from other publications. This targeted search             
provided a more detailed knowledge, along with extensive information. For every publication            
used, the Impact Factor (IF) of the journal and the number of Citations were consulted. The                
catalogue was completed with publications provided by Dr. Gómez-Durán. 
 
 
Fig. 9: Scheme of the workflow followed during the bibliographic research. 
 
Keywords for information about mitochondria, OXPHOS and mitochondrial diseases were:          
‘mitochondria’, ‘oxidative phosphorylation system’, ‘OXPHOS’, ‘electron transport chain’,        
‘mitochondrial DNA’, ‘mitochondrial genome’, ‘mitochondrial disease’, ‘mitochondrial       




Keywords for metabolomics in MDs were: ‘metabolomics’, ‘metabolites’, ‘metabolism’, ‘amino          
acid metabolism’, ‘mitochondria’, ‘mitochondrial DNA’, ‘biomarker’, combining them with the          
Boolean operator ‘AND’. 
 
Keywords for mitochondrial dysfunction and stress mechanisms were: ‘mitochondria’,         
‘mitochondrial disease’, ‘mitochondrial disorder’, ‘mitochondrial dysfunction’, ‘mitochondrial       
stress’, ‘integrated stress response’, ‘activating transcription factor 4’, ‘ATF4’, ‘eukaryotic          
translation initiation factor 2 alpha’, ‘eIF2a’, ‘mammalian target of rapamycin complex I’,            
‘mTORC1’, combining them with the Boolean operator ‘AND’. 
II. Cell culturing 
Cell lines were a kind gift from the laboratory of Prof. Julio Montoya (University of Zaragoza),                
full description of the patients and mtDNA sequences of all the cell lines is described               
elsewhere​91​. Cell lines were grown in supplemented medium (SM) containing Dulbecco’s           
modified eagle medium (DMEM) containing glucose (4.5 g/l), pyruvate (0.11 g/l) (Gibco, ref.:             
41966_029), uridine (100ug/ml) and fetal bovine serum (FBS) (5 %) (Gibco, ref.: 10270_106)             
without antibiotics at 37ºC and 5% CO2 conditions. All the experiments were performed in at               
least 2 technical repeats. 
 
Defrosting cells. Cells were transferred from cryovials into Falcon tubes containing 4-5 mL             
of SM. Cells were centrifuged at 1200g for 5 min and supernatant was discarded. The pellet                
was then resuspended in SM and cells were seeded in 100mm plates containing 8-10 mL of                
SM, then incubated at 37ºC and 5% CO2 until confluence was reached. 
 
Passing cells. When cells reached ~90% confluence the medium was discarded and the             
plate was washed with PBS. PBS was discarded and 1 mL of trypsin-EDTA (0.05%) (Gibco,               
2300_054) was added to detach the cells from the plate. Cells were put back in the incubator                 
at 37ºC and 5% CO2 for 3-5 min. Cells were observed at the microscope to check for                 
dettaching. To stop trypsinization, cells were resuspended in SM by pipetting up and down,              
and after that were transferred to a new plate with a fresh SM. Cells were then incubated at                  
37ºC and 5% CO2 until the desired confluence level was reached. 
 
Freezing cells. Cells were trypsinized as described previously. After detaching, cells were            
centrifuged at 1200g for 5 min and supernatant was discarded. After centrifugation, pellets             
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were resuspended with freezing media (FM) composed of FBS and dimethylsulfoxide           
(DMSO) (10%) at 1.5-3 x 10​6 cells/ml. DMSO is a cryoprotectant that must be added in order                 
to prevent cells from death due to formation of water crystals. Approximately, 1 mL of the                
mixture of resuspended cells in FM was transferred to each cryovial. Quickly after that the               
cryovials were stored at -80ºC in expanded polystyrene boxes to allow a progressive             
decrease in temperature by 1ºC/hour and thus cryopreservation of the cells. The day after              
the frozen cryovials and then transferred to the liquid nitrogen (N​2(l)​) for long term storage.  
III. Denaturing electrophoresis and Western blot analysis. 
Protein extraction and quantification​. Total protein extracts were prepared according to           
each protein’s solubilities. Protein extracted for kinase phosphorylation analysis was          
extracted using PathScan® Sandwich ELISA Lysis Buffer from Cell signaling. Protein           
concentrations were measured using Bradford reagent and following manufacturer's         
conditions. 
 
Electrophoresis​. In any case protein extracts (30ug) were loaded on NuPAGE® Bis-Tris            
Precast Midi Protein Gels with MES (Invitrogen®) with 26 wells. Electrophoresis was carried             
out following the manufacturer's conditions. SeeBlue® Plus2 Pre-stained Protein Standard          
from Invitrogen® was used in each electrophoresis as protein size markers. 
 
Transfer​. The separated proteins were transferred to polyvinylidene fluoride membranes          
using the iBLOT system (Invitrogen®) or Mini Trans-Blot® transfer system from Biorad®. 
 
Immunoblotting and detection. ​The resulting blots were blocked for 1 h with 5% nonfat dry               
milk in Tris-Buffered Saline, 0.1% TWEEN® 20 (TBST) and probed overnight at 4ºC with              
primary antibodies in TBST with 5% Bovine serum albumin (BSA) or nonfat dry milk using the                
appropriate concentration as per the manufacturer's conditions with small adaptations (Table           
3). After the primary antibody, blots were incubated for 1 h with secondary antibodies in               
TBST with 5% BSA (Bovine serum albumin or nonfat dry milk) conjugated with horseradish              
peroxidase (HRP) and immuno-detected using an Amersham Imager 600. 
 
Immunoblotting imaging and quantification. ​The bands for each antibody were quantified,           
aligned and cropped using the Fiji program and the OD was used as a value for statistical                 
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purposes. In order to avoid inter-blot variation one cell line was used as an internal control                
and the values of the OD corrected by β-Actin were relative to it in each case. 
 
Antibody Code Commercial Concentration 
4EBP1 ab32130 Abcam 1 in 1000 
Phospho-4EBP1​Ser65 9451 Cell signalling 1 in 500 
EIF2A 9722 Cell signalling 1 in 500 
Phospho-EIF2A​Ser51​ (D9G8) 3398 Cell signalling 1 in 500 
IRE1a 3294T Cell signalling 1 in 500 
PERK 5683T Cell signalling 1 in 500 
BIP 3177T Cell signalling 1 in 500 
ATF5 ab184923 Abcam 1 in 1000 
ATF4 sc-390063 Santa Cruz Biotechnology 1 in 500 
HSP10 sc-376313 Santa Cruz Biotechnology 1 in 500 
B-Actin a1978 Sigma 1 in 2000 
Vinculin V4505 Sigma 1 in 1000 
 
Table 3: Antibodies used for immunodetection of proteins. The commercial, its           
code and concentration are indicated. 
IV. Real-time PCR quantification of transcripts.  
Total RNA was isolated from cells exponentially growing using an RNA isolation kit from              
Qiagen® according to the manufacturer's protocol. Quantification of mRNA by real-time PCR            
(RT-PCR) was carried out using the High capacity cDNA reverse transcription kit (Applied             
Biosystems) following the manufacturer's conditions. The mRNA levels were determined          
using probes from Applied Biosystems and following MQIE guidelines​92​. The expression           
levels were normalized with glyceraldehyde-3-phosphate dehydrogenase (GADPH) and        
B-ACTIN as housekeeping genes. The codes of each of the probes are included in Table 4.                
The comparative Cq method was used for relative quantification of gene expression.            
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Differences in the Cq values (dCq) of the transcript of interest and the reference gene were                
used to determine the relative expression of the gene in each sample. The ddCq method was                
used to calculate the fold change (FC) of expression compared to the controls. 
 
Name Description Product Number 
ACTB actin beta Hs01060665_g1 
ATF4 activating transcription factor 4 Hs00909569_g1 
ATF5 activating transcription factor 5 Hs01119208_m1 
ATF6 activating transcription factor 6 Hs00232586_m1 
GAPDH glyceraldehyde-3-phosphate dehydrogenase Hs02786624_g1 
 
Table 4: Probes used for RT-qPCR amplification. ​Product number of each probe is indicated. 
V. Statistical analysis and graphics 
Graphics were created with Excel. In the Western blot quantification, relative protein levels             
corrected by loading control are shown. Graphics show mean values ± standard deviation             
(SD) of the technical replicates. 
 
Statistical analysis and graphic design was performed using Excel. Mean values of each             
technical replicate were compared using 1 factor ANOVA with a level of significance of              
p<0.05. Then, unpaired t-student tests of each variant vs. control were performed with a level               




Case-study: Unmasking the mechanisms of stress in cell lines with mutations           
causing LHON.  
 
Leber’s Hereditary Optic Neuropathy (LHON) is a mitochondrial disorder (MD) caused by            
mutations in the mitochondrial genome (mtDNA). Usually these mutations sit on genes            
encoding subunits of the complex I of the oxidative phosphorylation system (OXPHOS) - the              
system responsible for the synthesis of energy of the cell. The three commonest mutations              
causing LHON are non-synonym changes (see Section III.A)​12​. 
 
LHON is characterized by a central vision loss due to degeneration of retinal ganglion cells               
(RGCs). Being caused by mutations in the mtDNA, LHON is maternally inherited, but it's              
penetrance is incomplete as not all the carriers of the mutation develop the disease, which               
affects mostly young males. Moreover, environmental and mtDNA genetic factors also           
contribute to this variability but are not enough to explain it. The exact pathophysiological              
mechanism of the disease is yet unknown. Thus, other compensatory mechanisms might act             
as potential candidates to answer this question. 
 
Recent observations in models of MDs such as the mutated Twinkle helicase (model of              
mtDNA deletions)​66​, Ndufs4 KO mouse (model of complex I dysfunction)​57 have shown            
different responses of cellular stress which might be related with the metabolic rewiring             
observed in these disorders. Most of the observations have proposed a link between the              
mitochondrial dysfunction and the activation of the integrated stress response (ISR) as well             
as mitochondrial unfolded protein response (mtUPR)​66​. Discovering how these processes are           
involved in the pathogenesis of LHON and other MDs would enlighten the way to              
understanding its complexity and finding new therapeutic options. 
 
A. eIF2A is activated in m.3460G>A  
The activation of the eukaryotic translation initiation factor 2 alpha (eIF2A) is the common              
point in which the different activators (HRI, PKR, PERK and GCN2) of the ISR converge​78​. As                
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eIF2A is activated in mitochondrial stress​42,59​, we decided to check its phosphorylation state             
in LHON cell lines. 
 
We observed that eIF2A activation is increased in cell lines carrying the m.3460G>A/             
p.MT-ND1:A52T mutation but not in cells carrying m.11778G>A/ p. MT-ND4:R340H. Given           
that the observed p-value is almost 0.05 (p=0.0675), but we consider that further             
experiments are needed to refuse the hypothesis in this case. 
 
Fig. 10: Quantification of p.eIF2A​Ser51​ in LHON cell lines compared to control.  
A) Immunodetection of eIF2A: eukaryotic initiation factor 2 alpha subunit and its            
phosphorylated form p.eIF2A. Gels were run, transferred and immunoblotted         
simultaneously using B-Actin as loading control. Size and name of each protein are             
indicated. 
B) Relative quantification (to average of controls) of the levels of p.eIF2A​Ser51 protein             
corrected by loading are shown. Levels correspond to        
phosphorylated/non-phosphorylated ratio. Two control cell lines and one cell line per           
LHON variant were analysed. The data represents 3 independent technical          
experiments for each cell line ± standard deviation (SD) of the mean. Statistical testing              
was performed by using a 1-way-ANOVA test followed by unpaired t-test to compare             
each mutant to the controls. Exact p-values corrected for t-student are indicated.  
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B. mTORC1 is activated in m.11778G>A 
mTORC1 is a nutrient sensor that controls cell growth and protein synthesis, and other              
cellular processes such as autophagy, the pentose phosphate pathway and ​de novo            
nucleotide and lipid synthesis​64,65​. Studies on MDs models have shown activation of            
mTORC1 is activated in LHON​71​, Leigh syndrome​93​, mitochondrial myopathy​66,73 and          
thymidine kinase 2 deficiency​72​. Moreover, it's been shown that mTORC1 controls ATF4            
expression and translation through 4EBP1​94​. 4EBP1 is a downstream target of mTORC1.            
Thus, we measured the levels of activation as a surrogate of mTORC1 activation in LHON               
cell lines. 
 
We saw a significant activation of 4EBP1 in cells carrying the m.11778G>A/ p.             
MT-ND4:R340H mutation, but not in those carrying m.3460G>A/ p.MT-ND1:A52T. 4EBP1 is           





Fig. 11: Quantification of p.4EBP1​Ser65​ in LHON cell lines compared to control.  
A) Immunodetection of 4EBP1: EIF4E binding protein 1 and its phosphorylated form            
p.4EBP1​Ser65​. Gels were run, transferred and immunoblotted simultaneously using         
B-Actin as loading control. Size and name of each protein are indicated. 
B) Relative quantification (to average of controls) of the levels of p.4EBP1​Ser65 ​protein             
corrected by loading are shown. Levels correspond to        
phosphorylated/non-phosphorylated ratio. Two control cell lines and one cell line per           
LHON variant were analysed. The data represents 3 independent technical          
experiments for each cell line ± standard deviation (SD) of the mean. Statistical             
testing was performed by using a 1-way-ANOVA test followed by unpaired t-test to             
compare each mutant to the controls. Exact p-values corrected for unpaired t-student            
are indicated. 
C. No differences are observed in PERK levels 
PERK is one of the four eIF2A kinases and mainly responds to ER stress​78​. As eIF2A is                 
activated in cell lines carrying the m.3460G>A/ p.MT-ND1:A52T mutation, we asked if this             
activation derives from ER stress or other stimuli. 
 
Furthermore, PERK activation has been previously observed in LHON​42​. In contrast with this,             





Fig. 12: Quantification of PERK in LHON cell lines compared to control.  
A) Immunodetection of PERK: protein kinase R-like ER kinase. Gels were run,            
transferred and immunoblotted simultaneously using B-Actin as loading control. Size          
and name of each protein are indicated. 
B) Relative quantification (to average of controls) of the levels of PERK protein             
corrected by loading are shown. Two control cell lines and one cell line per LHON               
variant were analysed. The data represents 2 independent technical experiments for           
each cell line ± standard deviation (SD) of the mean. Statistical testing was performed              
by using a 1-way-ANOVA test followed by unpaired t-test to compare each mutant to              
the controls. Exact p-values corrected for unpaired t-student are indicated. 
D. mtUPR is not activated in LHON cell lines 
Under stressful conditions such as ER stress​95 or amino acid deprivation​84​, ATF4 translation             
is activated by p.eIF2A. ATF4 is the best characterized effector of the ISR and regulates               
genes such as CHOP, ATF3, ASNS or GADD34​78​. Furthermore, ATF4 has a suspected role              
in MDs as mitochondrial dysfunction leads to ATF4 activation​52,59,87​. This involvement could            
be key in the metabolic rewiring that cells undergo in MDs, as it induces changes in amino                 
acid uptake and biosynthesis, the folate cycle, FGF21 and autophagy (see Introduction,            
Section V.C). One of the effects of ATF4 activation is the triggering of the mtUPR. HSP10                
and ATF5 are effectors of the mtUPR​86​. As eIF2A is activated, we checked for ATF4 and                
mtUPR protein levels in LHON cell lines. 
 
We did not observe changes on protein levels of ATF4 or its downstream targets ATF5 and                




Fig. 13: Quantification of mtUPR proteins in LHON cell lines compared to control.  
A) Immunodetection of ATF4: activating transcription factor 4; ATF5: activating          
transcription factor 5; HSP10: heat-shock 10 kDa protein. Gels were run, transferred            
and immunoblotted simultaneously using B-Actin as loading control. Size and name of            
each protein are indicated. 
B) Relative quantification (to average of controls) of the levels of protein corrected by              
loading are shown. Two control cell lines and one cell line per LHON variant were               
analysed. The data represents 2 independent technical experiments for each cell line ±             
standard deviation (SD) of the mean. Statistical testing was performed by using a             
1-way-ANOVA test followed by unpaired t-test to compare each mutant to the controls.             
Exact p-values corrected for unpaired t-student are indicated. 
E. ATF4 is transcriptionally downregulated in m.3460G>A cell line 
Apart from being translationally regulated by eIF2A and in an mTORC1-dependent manner,            
ATF4 is also transcriptionally upregulated by mTORC1​94​. We showed no changes on ATF4             
protein levels (see Results, Section D) in any of the LHON cell lines compared to the controls                 
and so studied the mRNA levels in order to know if they might follow a different trend. We                  
also measured the levels of transcripts ATF3, a known downstream target of ATF4 involved              
in MDs​67​. 
 
We observed a significant downregulation of the levels of mRNA of ATF4 in cell lines               
carrying the m.3460G>A/ p.MT-ND1:A52T mutation, but not on those carrying m.11778G>A/           
p. MT-ND4:R340H. Yet, no differences in ATF3 mRNA levels were observed in any of the               




Fig. 14: mRNA fold change of ATF3 and 4 in LHON cell lines compared to               
control. ​Three control cell lines and one cell line per LHON mutation were analyzed.              
Data represents 3 independent technical replicates for each cell line ± standard            
deviation (SD) of the mean. Statistical testing was performed by using a            
1-way-ANOVA test followed by unpaired t-test to compare each mutant to the            
controls. Exact p-values corrected for unpaired t-student are indicated. 
F. ER stress is not activated in cell lines carrying LHON mutations 
ER stress is not only sensed by PERK, but also by IRE1a and ATF6​96​. As PERK signalling is                  
not activated in LHON, we asked whether other PERK-independent ER stress upstream            
regulators were responsible for the eIF2A activation.  
 
In keeping with the previous findings in PERK (see Results, Section C) we did not see any                 
changes in the labels of proteins of protein IRE1a and ER stress effector BiP in LHON cell                 




Fig. 15: Quantification of ER stress proteins in LHON cell lines compared to control.  
A) Immunodetection of IRE1a: serine/threonine-protein kinase/endoribonuclease IRE1a; BiP:        
binding immunoglobulin protein. Gels were run, transferred and immunoblotted simultaneously          
using B-Actin and Vinculin as loading controls. Size and name of each protein are indicated. 
B) Relative quantification (to average of controls) of the levels of protein corrected by loading               
are shown. Two control cell lines and one cell line per LHON variant were analysed. The data                 
represents 2 independent technical experiments for each cell line ± standard deviation (SD) of              
the mean. Statistical testing was performed by using a 1-way-ANOVA test followed by unpaired              




Fig. 16: mRNA fold change of ATF6 in LHON cell lines compared to control. ​Three control                
cell lines and one cell line per LHON mutation were analyzed. Data represents 3 independent               
technical replicates for each cell line ± standard deviation (SD) of the mean. Statistical testing               
was performed by using a 1-way-ANOVA test followed by unpaired t-test to compare each              
mutant to the controls. Exact p-values corrected for unpaired t-student are indicated.  
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Discussion and conclusions 
 
Here, we studied the mRNA and protein levels of some stress-related proteins in two              
different mutations causing the disease of LHON. We aimed to understand whether a             
deregulation of these pathways is involved in the pathogenesis of the disease. We focused              
on pathways related with MDs such as mTORC1 and the axis PERK/eIF2a/ATF4 axis, both              
being found to be altered under MDs. 
 
First, we checked the levels of 4EBP1, a downstream target of mTORC1, whose             
phosphorylation state reflects mTORC1 activation and controls transcriptionally​66,94 and         
translationally the levels of the mito-stress sensor ATF4​94​. Similar to previous observations in             
the mutated Twinkle helicase​66 and ​Ndufs4​-KO​57 mouse model, we found that mTORC1 is             
activated in the cell lines carrying the mutation m.11778G>A/ p. MT-ND4:R340H, but not on              
those carrying the m.3460G>A/ p.MT-ND1:A52T, suggesting a mutation-specific phenotype.         
Indeed, while the m.3460G>A/ p.MT-ND1:A52T variant produces a 70% decrease in           
complex I activity, the m.11778G>A/ p. MT-ND4:R340H does not affect it​97​, implying a             
possible correlation between the complex deficiency and the activation of mTORC1 that            
needs to be further studied. 
 
eIF2A activation is a common hallmark in mitochondrial stress​42,59​. In keeping with previous             
findings, we observed an increased activation of eIF2A (see Results, Section A) in the cell               
lines carrying the m.3460G>A/ p.MT-ND1:A52T variant, supporting the mutation-specific         
stress response hypothesis. This phosphorylation state of eIF2A might be induced by several             
upstream signals such as heme-regulated eIF2a kinase I (HRI), protein kinase R (PKR) or              
general control non-derepressible 2 (GCN2) and PERK. We did not find differences in PERK              
levels (see Results, Section C) in any of the LHON mutations, contrary to previous findings in                
LHON fibroblasts​42​, pointing towards another mechanism that will be evaluated further on. 
 
Next, we studied whether the downstream effectors of eIF2A and mTORC1 were also             
differentially regulated. We focussed on ATF4 and its downstream targets such as ATF3​67​,             
ATF5​66,67 and HSP10 as they are widely associated with MDs and the mtUPR​59,66,67​.             
Surprisingly, we did not see any changes in the levels of proteins and mRNA of all the                 
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downstream targets of ATF4 suggesting that mtUPR is not activated in LHON cell lines. We               
did, however, observe a striking decrease in the ATF4 mRNA levels in the cell lines carrying                
the m.3460G>A/ p.MT-ND1:A52T that needs to be further studied. 
 
Lastly, we investigated if other targets of the endoplasmic reticulum (ER) stress independent             
of PERK, such as IRE1a and ATF6 and its downstream target BIP, were activated by the                
LHON mutations. In agreement with PERK levels, there were no changes in the ATF6 mRNA               
levels and the protein levels of IRE1a and BiP (see Results, Section F). These findings               
confirm the absence of ER stress driven by LHON mutations. 
 
All together, our observations indicate a mutation specific stress response in each of the              
LHON mutations that needs to be further studied. Identifying all the involved elements and              
their impact in LHON pathogenesis is a key step to propose new drugs for treating the                
disease. In the future, more differences between mutations affecting other OXPHOS           
complexes or other aspects of mitochondrial functioning such as mtDNA maintenance and            
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